Abstract
Background: Thyroid cancer is the most common type of endocrine neoplasia. Differentiated thyroid carcinoma (DTC) represents 94% of all thyroid cancer types. Approximately 20% experience local recurrence and 10% distant metastasis. The recurrent DTC often becomes less differentiated, loses the iodine uptake capability and consequently loses the radioactive iodine treatment option. Under these circumstances survivability drops below 10% at 10 years. The treatment options for dedifferentiated thyroid cancers are extremely limited. This category sometimes referred to as poorly differentiated thyroid cancer (PDTC), is characterised by a missing response to radioiodine treatment and a remarkably reduced survivability. Therefore, new drugs have been developed to fill this gap in treatment.
Methods: The goal of this work is to review the effects and roles of the multikinase inhibitors sorafenib, sunitinb and lenatinib in thyroid cancer.
Results: The new tyrosine kinase inhibitors (TKIs) aimed to inhibit tumour angiogenesis. Current clinical trials with novel drugs have shown promising results. A phase III trial (DECISION) of sorafenib in radioiodine (RAI)-refractory thyroid cancer showed a median progression-free survival (PFS) of 10.8 months in the sorafenib group, compared to 5.8 months in the placebo group. Sunitinib, another TKI, exhibited significant antitumour effects in patients with advanced DTC. Nevertheless, treatment with TKIs can lead to the development of resistance against these anti-angiogenic treatments, partly due to compensatory mechanisms. Lenvatinib, the recently approved drug for RAI-refractory thyroid cancer, blocks a different receptor than the currently available drugs. Lenvatinib inhibits fibroblast growth factor receptor (FGFR), as well as other receptors. FGFR plays a key role in the development of resistance against anti-angiogenic drugs. In a phase III trial (SELECT) on RAI-refractory DTC, the lenvatinib group showed a PFS of 18.3 months, compared to 3.6 months in the placebo group. This led to the approval of lenvatinib, the first drug capable of reversing anti-angiogenic mechanisms.
Conclusion: The frequently adverse effects seen in TKI treatment require further investigation. A well-adjusted balance between efficacy and adverse effects is desirable. No effects on overall survival were reported. Therefore, further studies are required.
Keywords: Thyroid cancer, clinical trials, tyrosine kinase inhibitors, sorafenib, sunitinib, lenvatinib.
Current Pharmaceutical Design
Title:Effects and Role of Multikinase Inhibitors in Thyroid Cancer
Volume: 22 Issue: 39
Author(s): Rasmus Laursen, Markus Wehland, Sascha Kopp, Jessica Pietsch, Manfred Infanger, Jirka Grosse and Daniela Grimm
Affiliation:
Keywords: Thyroid cancer, clinical trials, tyrosine kinase inhibitors, sorafenib, sunitinib, lenvatinib.
Abstract: Background: Thyroid cancer is the most common type of endocrine neoplasia. Differentiated thyroid carcinoma (DTC) represents 94% of all thyroid cancer types. Approximately 20% experience local recurrence and 10% distant metastasis. The recurrent DTC often becomes less differentiated, loses the iodine uptake capability and consequently loses the radioactive iodine treatment option. Under these circumstances survivability drops below 10% at 10 years. The treatment options for dedifferentiated thyroid cancers are extremely limited. This category sometimes referred to as poorly differentiated thyroid cancer (PDTC), is characterised by a missing response to radioiodine treatment and a remarkably reduced survivability. Therefore, new drugs have been developed to fill this gap in treatment.
Methods: The goal of this work is to review the effects and roles of the multikinase inhibitors sorafenib, sunitinb and lenatinib in thyroid cancer.
Results: The new tyrosine kinase inhibitors (TKIs) aimed to inhibit tumour angiogenesis. Current clinical trials with novel drugs have shown promising results. A phase III trial (DECISION) of sorafenib in radioiodine (RAI)-refractory thyroid cancer showed a median progression-free survival (PFS) of 10.8 months in the sorafenib group, compared to 5.8 months in the placebo group. Sunitinib, another TKI, exhibited significant antitumour effects in patients with advanced DTC. Nevertheless, treatment with TKIs can lead to the development of resistance against these anti-angiogenic treatments, partly due to compensatory mechanisms. Lenvatinib, the recently approved drug for RAI-refractory thyroid cancer, blocks a different receptor than the currently available drugs. Lenvatinib inhibits fibroblast growth factor receptor (FGFR), as well as other receptors. FGFR plays a key role in the development of resistance against anti-angiogenic drugs. In a phase III trial (SELECT) on RAI-refractory DTC, the lenvatinib group showed a PFS of 18.3 months, compared to 3.6 months in the placebo group. This led to the approval of lenvatinib, the first drug capable of reversing anti-angiogenic mechanisms.
Conclusion: The frequently adverse effects seen in TKI treatment require further investigation. A well-adjusted balance between efficacy and adverse effects is desirable. No effects on overall survival were reported. Therefore, further studies are required.
Export Options
About this article
Cite this article as:
Laursen Rasmus, Wehland Markus, Kopp Sascha, Pietsch Jessica, Infanger Manfred, Grosse Jirka and Grimm Daniela, Effects and Role of Multikinase Inhibitors in Thyroid Cancer, Current Pharmaceutical Design 2016; 22 (39) . https://dx.doi.org/10.2174/1381612822666160614084943
DOI https://dx.doi.org/10.2174/1381612822666160614084943 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic :Current Advances In Therapeutic Applications of Nuclear Receptors (Guest Editor: Stefano Fiorucci)]
Current Topics in Medicinal Chemistry Ghrelin and Energy Balance: Focus on Current Controversies
Current Drug Targets Mean Platelet Volume: A Link Between Thrombosis and Inflammation?
Current Pharmaceutical Design Hashimotos Thyroiditis: From Genes to the Disease
Current Genomics Ellipticine, its Derivatives: Re-evaluation of Clinical Suitability with the Aid of Drug Delivery Systems
Current Cancer Drug Targets Sesterterpenoids with Anticancer Activity
Current Medicinal Chemistry Novel Therapeutic Approaches to Autoimmune Demyelinating Disorders
Current Pharmaceutical Design Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design Ghrelin: New Insight to Mechanisms and Treatment of Postoperative Gastric Ileus
Current Pharmaceutical Design Vascular Endothelial Growth Factor: A New Paradigm for Targeting Various Diseases
Current Angiogenesis (Discontinued) Peptidic Tumor Targeting Agents: The Road from Phage Display Peptide Selections to Clinical Applications
Current Pharmaceutical Design Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Screening the Receptorome Yields Validated Molecular Targets for Drug Discovery
Current Pharmaceutical Design Employing Genetic Markers to Improve Diagnosis of Thyroid Tumor Fine Needle Biopsy
Current Genomics Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Multifunctional Proteins in Tumorigenesis: Aminoacyl-tRNA Synthetases and Translational Components
Current Proteomics Anticancer Activity of the Bioreductive and Non-Bioreductive Zerumbone Derivatives
Letters in Drug Design & Discovery Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets A Novel Bromomelatonin Derivative Suppresses Apoptosis with Regulating the Expression of Bcl-2 Family Genes
Letters in Drug Design & Discovery Lipids as Biomarkers of Cancer and Bacterial Infections
Current Medicinal Chemistry